What are tolvaptan and hereditary sensory neuropathy (HSN)?

Tolvaptan and HSN: Two Distinct Medical Entities

Tolvaptan is a vasopressin V2-receptor antagonist medication used to slow kidney disease progression in autosomal dominant polycystic kidney disease (ADPKD), while HSN (hereditary sensory neuropathy) is a group of inherited peripheral nerve disorders affecting sensory and autonomic neurons—these are completely unrelated conditions.

Tolvaptan

What It Is

Tolvaptan is a selective vasopressin V2-receptor antagonist that blocks the action of antidiuretic hormone (arginine vasopressin) on kidney cystic epithelium 1, 2. The drug increases urine water excretion (aquaresis), decreases urine osmolality, and raises serum sodium concentrations without significantly affecting sodium or potassium excretion 2.

Primary Indication

Tolvaptan is the cornerstone pharmacotherapy for ADPKD patients at risk of rapid kidney disease progression 1. The 2025 KDIGO guidelines establish it as the primary intervention targeting vasopressin action in ADPKD 1.

Clinical Effectiveness

The drug demonstrates meaningful disease modification:

• Slows eGFR decline by 1.3 mL/min/1.73 m² per year (95% CI: 1.0-1.7) 1
• Reduces total kidney volume growth by 2.7% (95% CI: -3.3% to -2.1%) 1
• Decreases incidence of UTIs, kidney stones, hematuria, and kidney pain events 1

Real-world effectiveness data from US clinical practice confirms these benefits, showing slower eGFR decline by 1.40 mL/min/1.73 m² per year compared to historical controls 3.

Dosing Protocol

Initial dose: 45 mg upon waking + 15 mg 8 hours later 1

Titration schedule:

• Uptitrate at ≥1 week intervals 1
• Target dose: 90 mg AM + 30 mg PM 1
• Continue until approaching kidney replacement therapy 1

Downtitrate or hold for:

• Concurrent CYP3A inhibitors (strong: ketoconazole, clarithromycin, ritonavir; moderate: diltiazem, erythromycin, grapefruit juice) 1
• Intolerance or side effects 1
• Elevated liver enzymes 1

Critical Safety Considerations

Hepatotoxicity (Black Box Warning):

• Mandatory monthly liver function tests for first 18 months, then every 3 months 1
• Approximately 5% develop transaminase elevation >3× upper limit of normal (vs. 1% placebo) 1
• Permanently discontinue if AST/ALT ≥3× ULN or >2× baseline with symptoms (fatigue, nausea, vomiting, right upper quadrant pain, jaundice, pruritus) 1
• Most liver injuries occur within first 18 months and resolve within 1-4 months after cessation 1

Volume Depletion Management:

• Patients must maintain adequate water intake to replace urinary losses 1
• Implement "sick-day plan": skip doses during volume depletion risk (limited water access, increased fluid losses, warm weather activities, vomiting, diarrhea) 1
• Counsel patients to drink sugar-free, fat-free liquids and adopt low-sodium intake to reduce polyuria 1

Osmotic Demyelination Syndrome Risk:

• Can occur with rapid sodium correction, particularly in patients with liver disease, malnutrition, chronic alcoholism, or severe baseline hyponatremia 2
• Treatment must be initiated/restarted only in hospital settings where sodium can be monitored closely 2

Practical Considerations

• Can be continued in patients >55 years or eGFR <25 mL/min/1.73 m² if well tolerated 1
• Causes small, reversible eGFR reduction reflecting impact on compensatory hyperfiltration 1
• Take with or without food; avoid grapefruit juice 2
• Do not use in ADPKD patients outside monitored programs due to liver injury risk 2

---

HSN (Hereditary Sensory Neuropathy)

What It Is

Hereditary sensory and autonomic neuropathies (HSN/HSAN) are clinically and genetically heterogeneous inherited disorders of the peripheral nervous system that predominantly affect sensory and autonomic neurons 4.

Clinical Features

Hallmark manifestations include:

• Prominent sensory signs and symptoms 4
• Ulcerative mutilations 4
• Variable autonomic disturbances 4
• Variable motor involvement 4

Genetic Basis

• Both autosomal dominant and autosomal recessive inheritance patterns 4
• Disease-causing mutations identified in 11 genes 4
• HSN type 1 most frequently caused by mutations in SPTLC1 or SPTLC2 genes (encoding serine palmitoyltransferase subunits) 5

Pathophysiology

Affected proteins involve:

• Nerve-specific roles 4
• Sphingolipid metabolism 4, 5
• Vesicular transport 4
• Structural integrity 4
• Transcription regulation 4

In HSN-1 specifically, SPT mutations cause production of atypical deoxysphingoid bases (deoxysphingamine and deoxymethylsphingamine) rather than normal sphinganine 5. These abnormal compounds cause:

• Dose- and time-dependent neurotoxicity 5
• Abnormal calcium handling by endoplasmic reticulum and mitochondria 5
• Dysregulation of store-operated calcium channels 5
• Early mitochondrial membrane potential loss 5

Diagnostic Approach

For suspected hereditary neuropathies, the 2009 AAN/AANEM/AAPM&R guideline recommends:

1. Determine if neuropathy is demyelinating or axonal via electrodiagnostic studies 6
2. Ascertain inheritance pattern (autosomal dominant, recessive, or X-linked) 6
3. Genetic testing is established as useful for accurate diagnosis and classification (Class I evidence) 6
4. For cryptogenic polyneuropathy with classical hereditary phenotype, routine screening for CMT1A duplication/deletion and Cx32 mutations may be useful 6

---

Key Distinction

These are entirely separate medical entities with no relationship:

• Tolvaptan = pharmacologic agent for ADPKD kidney disease
• HSN = inherited peripheral neuropathy disorder

The question likely arose from confusion between the acronyms or a misunderstanding about medical terminology.